ALA Study

Study: Alpha Lipoic Acid in Geographic Atrophy

ClinicalTrials.gov Identifier: NCT02613572

ALA: Evaluation of Lipoic Acid as a Treatment for Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD): Phase I- Tolerability Study and Phase II Pilot- Determine the Effects of ALA on the Progression of Geographic Atrophy (GA) in Patients With Age-Related Macular Degeneration (AMD).

Condition: Age-Related Macular Degeneration

Study Type: Interventional

Duration: 72 weeks

Eligibility:

Ages: 55 years to 90 years
Sexes: All
Accepts Healthy Volunteers: Yes

For additional information on this study, please click here

Back to Clinical Research